RU98104128A - METHODS AND COMPOSITIONS USEFUL TO SUPPRESS ANGIOGENESIS MEDIATED BY β5 - Google Patents

METHODS AND COMPOSITIONS USEFUL TO SUPPRESS ANGIOGENESIS MEDIATED BY β5

Info

Publication number
RU98104128A
RU98104128A RU98104128/14A RU98104128A RU98104128A RU 98104128 A RU98104128 A RU 98104128A RU 98104128/14 A RU98104128/14 A RU 98104128/14A RU 98104128 A RU98104128 A RU 98104128A RU 98104128 A RU98104128 A RU 98104128A
Authority
RU
Russia
Prior art keywords
angiogenesis
tissue
following structure
specified
organic mimetic
Prior art date
Application number
RU98104128/14A
Other languages
Russian (ru)
Other versions
RU2214268C2 (en
Inventor
Брукс Питер
Э.Череш Дэвид
Фредлэндер Мартин
Original Assignee
Дзе Скриппс Рисерч Инститьют
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Скриппс Рисерч Инститьют filed Critical Дзе Скриппс Рисерч Инститьют
Publication of RU98104128A publication Critical patent/RU98104128A/en
Application granted granted Critical
Publication of RU2214268C2 publication Critical patent/RU2214268C2/en

Links

Claims (1)

1. Способ подавления ангиогенеза в ткани, содержащей αvβ5, включающий введение в указанную ткань композиции, содержащей ингибирующее ангиогенез количество αvβ5 антагониста.1. A method of suppressing angiogenesis in a tissue containing α v β 5 , comprising introducing into said tissue a composition comprising an angiogenesis inhibiting amount of an α v β 5 antagonist. 2. Способ по п.1, в котором указанный αvβ5 антагонист представляет собой моноклональное антитело, иммуноспецифичное к αvβ5, но не к αvβ1, αvβ3 или αIIbβ5.
3. Способ по п.2, в котором указанное моноклональное антитело имеет иммунореактивные характеристики моноклонального антитела, обозначенного Р1F6.2. The method according to claim 1, in which the specified α v β 5 antagonist is a monoclonal antibody immunospecific to α v β 5 , but not to α v β 1 , α v β 3 or α IIb β 5 .
3. The method of claim 2, wherein said monoclonal antibody has immunoreactive characteristics of a monoclonal antibody designated P1F6. 4. Способ по п.1, в котором указанный αvβ5 антагонист представляет собой RGD-содержащий полипептид.4. The method according to claim 1, wherein said α v β 5 antagonist is an RGD-containing polypeptide. 5. Способ по п. 4, в котором указанный полипептид выбирают из группы, состоящей из цикло (Аrg-Gly-Аsр-D-Рhе-Vа1) (SEQ ID .4), цикло(Gly-D-Аrg-Gly-Аsр-Рhе-Vа1) (SEQ ID No.6), цикло(Аrg-Gly-Аsр-Рhе-D-Vа1) (SEQ ID .7), Туr-Тhr-Аlа-Glu-Сys-Lys-Рrо-Gln-Vаl-Тhr-Аrg-Gly-Аsр-Vаl-Рhе (SEQ ID .8), и цикло(Аrg-Gly-Аsр-D-Рhе-Аsn-МеVаl (SEQ ID .9). 5. The method of claim 4, wherein said polypeptide is selected from the group consisting of cyclo (Arg-Gly-Asp-D-Phe-Va1) (SEQ ID. 4), cyclo (Gly-D-Arg-Gly-Asp -Phe-Va1) (SEQ ID No.6), cyclo (Arg-Gly-Asp-Phe-D-Va1) (SEQ ID .7), Tur-Thr-Ala-Glu-Cys-Lys-Pro-Gln- Val-Thr-Arg-Gly-Asp-Val-Phe (SEQ ID .8), and cyclo (Arg-Gly-Asp-D-Phe-Asn-MeVal (SEQ ID .9). 6. Способ по п. 5, в котором указанная соль представляет собой гидрохлорид. 6. The method of claim 5, wherein said salt is hydrochloride. 7. Способ по п.1, в котором указанная ткань представляет собой воспаленную ткань и упомянутый ангиогенез является ангиогенезом воспаленной ткани. 7. The method according to claim 1, wherein said tissue is inflamed tissue and said angiogenesis is angiogenesis of inflamed tissue. 8. Способ по п. 7, в котором указанная ткань является артритной. 8. The method of claim 7, wherein said tissue is arthritic. 9. Способ по п. 8, в котором указанная артритная ткань присутствует у млекопитающего с ревматоидным артритом. 9. The method of claim 8, wherein said arthritic tissue is present in a mammal with rheumatoid arthritis. 10. Способ по п. 1, в котором указанный ангиогенез имеется у больного с заболеванием глаз, выбранным из группы глазных заболеваний, состоящей из диабетической ретинопатии, связанной с возрастом пятнистой дегенерации, предлагаемого окулярного гистоплазмозиса, преждевременного развития ретинопатии и неоваскулярной глаукомы. 10. The method according to claim 1, wherein said angiogenesis is present in a patient with an eye disease selected from the group of eye diseases consisting of diabetic retinopathy, age-related spotted degeneration, proposed ocular histoplasmosis, premature development of retinopathy and neovascular glaucoma. 11. Способ по п. 1, в котором указанный ангиогенез имеется у пациента с неоваскулярным нарушением роговицы, выбранным из группы нарушений, состоящей из трансплантации роговицы, герпетического кератита, люэтического кератита, птеригиума и неоваскулярного паннуса, связанного с ношением контактных линз. 11. The method according to claim 1, wherein said angiogenesis is present in a patient with neovascular corneal disorder selected from a group of disorders consisting of corneal transplantation, herpetic keratitis, luetic keratitis, pterygium and neovascular pannus associated with wearing contact lenses. 12. Способ по п. 1, в котором указанная ткань является гемангиомой. 12. The method according to claim 1, wherein said tissue is a hemangioma. 13. Способ по п. 1, в котором указанная ткань является плотной опухолью или метастазами плотной опухоли и упомянутый ангиогенез представляет собой ангиогенез в опухоли. 13. The method of claim 1, wherein said tissue is a dense tumor or metastases of a dense tumor, and said angiogenesis is angiogenesis in the tumor. 14. Способ по п. 1, в котором указанный ангиогенез индуцирован цитокином. 14. The method of claim 1, wherein said angiogenesis is induced by a cytokine. 15. Способ по п. 14, в котором указанный цитокин выбирают из группы, состоящей из васкулярного эндотелиального фактора роста, трансформирующего фактор роста α и эпидермального фактора роста. 15. The method of claim 14, wherein said cytokine is selected from the group consisting of vascular endothelial growth factor, transforming growth factor α and epidermal growth factor. 16. Способ по п. 15, в котором указанный цитокин представляет собой васкулярный эндотелиальный фактор роста и упомянутый ангиогенез выбирают из группы, состоящей из ретинального ангиогенеза, ангиогенеза в роговице, ангиогенеза в опухоли и ангиогенеза в воспаленной ткани. 16. The method of claim 15, wherein said cytokine is a vascular endothelial growth factor and said angiogenesis is selected from the group consisting of retinal angiogenesis, angiogenesis in the cornea, angiogenesis in the tumor, and angiogenesis in inflamed tissue. 17. Способ по п. 1, в котором указанное ингибирующее ангиогенез количество составляет от около 2 мкМ до 5 мкМ. 17. The method according to claim 1, wherein said angiogenesis inhibiting amount is from about 2 μM to 5 μM. 18. Способ по п.1, в котором указанное введение включает внутриглазное, внутривенное, трансдермальное, внутримышечное или оральное введение. 18. The method according to claim 1, in which the specified introduction includes intraocular, intravenous, transdermal, intramuscular or oral administration. 19. Способ по п.1, в котором указанное введение проводят в сочетании с химиотерапией. 19. The method according to claim 1, in which the specified introduction is carried out in combination with chemotherapy. 20. Способ по п. 1, в котором указанное введение включает однократное введение дозы внутривенно. 20. The method of claim 1, wherein said administration comprises a single intravenous dose. 21. Способ по п.1, в котором указанный αvβ5 антагонист представляет собой органический миметик.21. The method according to claim 1, wherein said α v β 5 antagonist is an organic mimetic. 22. Способ по п.21, в котором указанный органический миметик имеет следующую структуру:
Figure 00000001

23. Способ по п. 21, в котором указанный органический миметик имеет следующую структуру:
Figure 00000002

24. Способ по п. 21, в котором указанный органический миметик имеет следующую структуру:
Figure 00000003

25. Способ по п. 21, в котором указанный органический миметик имеет следующую структуру:
Figure 00000004

26. Способ по п. 21, в котором указанный органический миметик имеет следующую структуру:
Figure 00000005

27. Способ по п. 21, в котором указанный органический миметик имеет следующую структуру:
Figure 00000006

28. Способ по п. 21, в котором указанный органический миметик имеет следующую структуру:
Figure 00000007

29. Способ по п. 21, в котором указанный органический миметик имеет следующую структуру:
Figure 00000008

30. Способ по п. 21, в котором указанный органический миметик имеет следующую структуру:
Figure 00000009
22. The method according to item 21, in which the specified organic mimetic has the following structure:
Figure 00000001

23. The method according to p. 21, in which the specified organic mimetic has the following structure:
Figure 00000002

24. The method according to p. 21, in which the specified organic mimetic has the following structure:
Figure 00000003

25. The method according to p. 21, in which the specified organic mimetic has the following structure:
Figure 00000004

26. The method according to p. 21, in which the specified organic mimetic has the following structure:
Figure 00000005

27. The method according to p. 21, in which the specified organic mimetic has the following structure:
Figure 00000006

28. The method according to p. 21, in which the specified organic mimetic has the following structure:
Figure 00000007

29. The method according to p. 21, in which the specified organic mimetic has the following structure:
Figure 00000008

30. The method according to p. 21, in which the specified organic mimetic has the following structure:
Figure 00000009
RU98104128/14A 1995-08-14 1996-08-13 METHODS AND COMPOSITIONS USEFUL FOR SUPPRESSING αvβ5-MEDIATED ANGIOGENESIS RU2214268C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51479995A 1995-08-14 1995-08-14
US08/514,799 1995-08-14

Publications (2)

Publication Number Publication Date
RU98104128A true RU98104128A (en) 2000-01-27
RU2214268C2 RU2214268C2 (en) 2003-10-20

Family

ID=24048748

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98104128/14A RU2214268C2 (en) 1995-08-14 1996-08-13 METHODS AND COMPOSITIONS USEFUL FOR SUPPRESSING αvβ5-MEDIATED ANGIOGENESIS

Country Status (19)

Country Link
EP (1) EP0844874B1 (en)
JP (2) JP4903921B2 (en)
KR (1) KR100516322B1 (en)
CN (2) CN101053561A (en)
AT (1) ATE308981T1 (en)
AU (1) AU726793B2 (en)
CA (2) CA2754102C (en)
CZ (1) CZ40998A3 (en)
DE (1) DE69635417T2 (en)
DK (1) DK0844874T3 (en)
ES (1) ES2250996T3 (en)
HU (1) HUP9802675A3 (en)
MX (1) MX9801228A (en)
NO (1) NO319264B1 (en)
RU (1) RU2214268C2 (en)
SK (1) SK18898A3 (en)
UA (1) UA84665C2 (en)
WO (1) WO1997006791A1 (en)
ZA (1) ZA966886B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2256543C (en) * 1996-05-31 2010-12-07 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
EP0963370B1 (en) * 1996-12-09 2003-03-19 Eli Lilly And Company Integrin antagonists
US6245809B1 (en) 1996-12-09 2001-06-12 Cor Therapeutics Inc. Integrin antagonists
US6228985B1 (en) 1998-05-21 2001-05-08 Schering Corporation Derivatives of aminobenzoic and aminobiphenylcarboxylic acids useful as anti-cancer agents
GB9812019D0 (en) * 1998-06-05 1998-07-29 Zeneca Ltd Chemical compounds
ID30299A (en) 1998-06-05 2001-11-22 Astrazeneca Ab OKSAZOLIDINON DERIVES, THE PROCESS OF MAKING IT AND THE PHARMACY COMPOSITION THAT CONTAINS IT
US6759047B1 (en) 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US7387779B2 (en) 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US6235877B1 (en) 1999-08-04 2001-05-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
US6160099A (en) 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6344484B1 (en) 1999-02-12 2002-02-05 3-Dimensional Pharmaceuticals, Inc. Tyrosine alkoxyguanidines as integrin inhibitors
EP1028114A1 (en) 1999-02-13 2000-08-16 Aventis Pharma Deutschland GmbH Novel guanidine derivatives as inhibitors of cell adhesion
BR0012683A (en) 1999-07-21 2002-04-16 American Home Prod Selective bicyclic antagonists for the alpha-beta3 integrin
BR0007183A (en) 1999-09-29 2002-02-05 Ortho Mcneil Pharm Inc Isonipectoamides for the treatment of integrin-mediated disorders
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
KR100866666B1 (en) 2000-04-12 2008-11-04 지이 헬스케어 에이에스 Peptide-Based Compounds
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6486174B2 (en) 2000-08-07 2002-11-26 3-Dimensional Pharmaceuticals, Inc. Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
NO20004795D0 (en) 2000-09-26 2000-09-26 Nycomed Imaging As Peptide-based compounds
MXPA03006772A (en) 2001-01-29 2004-10-15 Dimensional Pharm Inc Substituted indoles and their use as integrin antagonists.
US7081460B2 (en) 2001-04-09 2006-07-25 Ortho-Mcneil Pharmaceutical, Inc. Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
PL207834B1 (en) 2001-07-10 2011-02-28 Ge Healthcare As Peptide-based compounds
HUP0401605A3 (en) 2001-08-01 2012-09-28 Merck Patent Gmbh Integrin inhibitors for the treatment of eye diseases
EP1722780A4 (en) 2003-11-26 2008-12-17 Univ Duke A method of preventing or treating glaucoma
US20050226865A1 (en) * 2004-04-02 2005-10-13 Regents Of The University Of California Methods and compositions for treating and preventing diseases associated with alphavbeta5 integrin
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
EP2374002A1 (en) 2008-12-23 2011-10-12 GE Healthcare UK Limited Application of 99mtc peptide-based compound as a bone marrow imaging agent
EP2822598A4 (en) 2012-03-05 2016-04-13 Univ Ramot Polymers having therapeutically active agents conjugated thereto, processes of preparing same and uses thereof
KR101597327B1 (en) 2014-04-24 2016-02-24 동아에스티 주식회사 Oxazolidine-based compound and selective androgen receptor agonists comprising the same
EP3419668A4 (en) 2016-02-24 2019-10-09 Ramot at Tel-Aviv University Ltd. Polymeric conjugates and uses thereof
RU2646125C1 (en) * 2016-09-20 2018-03-01 Константин Николаевич Руссков Method for recurrent pterygium prevention
RU2653814C1 (en) * 2017-06-01 2018-05-14 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Method of preventing recurrence of pterygium after surgical treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5235919A (en) * 1991-07-01 1993-08-17 Robuck Norman F Picnic table and flying insect control apparatus
UA43823C2 (en) * 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг PHARMACEUTICAL COMPOSITION FOR INTEGRIN INHIBITION <font face = "Symbol"> a </font> <sub> V </sub> <font face = "Symbol"> b </font> <sub> 3 </sub> cell adhesion mammal WAY treatment and prevention of diseases associated with cell adhesion DISORDERS, METHOD FOR BINDING LOCK integrin fibrinogen, a composition for wound healing
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
RU2195312C2 (en) * 1996-05-31 2002-12-27 Дзе Скриппс Рисерч Инститьют TECHNIQUES AND COMPOSITIONS USED TO INHIBIT αvβ5-CAUSED ANGIOGENESIS

Similar Documents

Publication Publication Date Title
RU2214268C2 (en) METHODS AND COMPOSITIONS USEFUL FOR SUPPRESSING αvβ5-MEDIATED ANGIOGENESIS
RU98104128A (en) METHODS AND COMPOSITIONS USEFUL TO SUPPRESS ANGIOGENESIS MEDIATED BY β5
RU2195312C2 (en) TECHNIQUES AND COMPOSITIONS USED TO INHIBIT αvβ5-CAUSED ANGIOGENESIS
ES2376850T3 (en) Useful procedures and compositions for inhibition of angiogenesis
JP2002515036A (en) Methods and compositions useful for inhibiting α ▲ VＶβ ▲ 5５mediated angiogenesis
KR20010102978A (en) Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
WO1997045447A9 (en) METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS
US7115263B2 (en) Compositions and methods for treating hyperimmune response in the eye
EP1223981B1 (en) Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye
US20060165703A1 (en) Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis
Grau et al. Host immune response and pathological expression in malaria: possible implications for malaria vaccines
Nakao et al. HTLV-I associated uveitis revisited: characteristic grey-white, granular deposits on retinal vessels.
WO2001072334A2 (en) Methods for treating disease with antibodies to cxcr3
US20050152902A1 (en) Treatment of diabetic retinopathy
JP3970311B1 (en) Neovascular inhibitor, DNA synthesis inhibitor, p44 / p42 MAPK phosphorylation inhibitor and medical kit
KR20120099862A (en) Pharmaceutical composition comprising neonatal fc receptor binding inhibitor
AU2006200359A1 (en) Use of a CD40:CD154 Binding Interruptor to Treat Immunological Complications of the Eye
WO2001000679A2 (en) Methods for inducing t cell non-responsiveness to a tissue or organ graft